New Zealand markets close in 4 hours 47 minutes

ABBV Jan 2025 220.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.73000.0000 (0.00%)
As of 10:51AM EDT. Market open.
Full screen
Previous close0.7300
Open0.7800
Bid0.6000
Ask1.0300
Strike220.00
Expiry date2025-01-17
Day's range0.7300 - 0.7800
Contract rangeN/A
Volume4
Open interest614
  • PR Newswire

    Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis

    AbbVie (NYSE: ABBV) today announced positive top-line results from SELECT-GCA, a Phase 3, multicenter, randomized, double-blind, placebo-controlled study, showing upadacitinib (RINVOQ®; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remissiona from week 12 through week 52 in adults with giant cell arteritis (GCA). In this study, 46 percent of patients receiving upadacitinib 15 mg in combination with a 26-week steroid taper regime

  • Zacks

    AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know

    AbbVie (ABBV) closed at $164.25 in the latest trading session, marking a +1.05% move from the prior day.

  • Reuters

    UPDATE 1-US FDA warns of harmful reactions to fake Botox injections

    The U.S. Food and Drug Administration on Tuesday alerted health care professionals and consumers that unsafe counterfeit versions of AbbVie's Botox were given to consumers for cosmetic purposes in multiple states. The U.S. Centers for Disease Control and Prevention (CDC) and the FDA are investigating reports of harmful reactions among people who received injections of counterfeit Botox. As of April 12, a total of 19 people from nine states had reported harmful reactions after receiving Botox injections from unlicensed or untrained individuals, or in non-healthcare settings, such as homes and spas, according to the CDC.